Foghorn Therapeutics
Anna Rivkin is an accomplished professional with extensive experience in business development and strategic leadership in the pharmaceutical industry. Currently serving as Chief Business Officer at Foghorn Therapeutics Inc., Anna has held various senior positions at Bristol Myers Squibb, including VP of Business Development and Transactions and VP of the Business Development Unit Head for multiple therapeutic areas. Additional roles at Bristol Myers Squibb include Executive Director of Search & Evaluation. Anna's background also includes directorship at Merck in Business Development & Licensing and experience as a Medical Affairs Liaison at CogniMed Inc. Anna earned a PhD in Neuroscience from Case Western Reserve University School of Medicine and a BA in Biology from The Johns Hopkins University.
This person is not in any teams
This person is not in any offices
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.